Regarding this issue, using transgenic mice with hepatic expression of human NPC1L1 under a liver-specific ApoE promoter (L1-Tg mice) [7], a recent study identified hepatic NPC1L1 as an NAFLD risk factor amendable to therapeutic intervention [11]. The gene discussed is NPC1L1; the disease is metabolic dysfunction-associated steatotic liver disease.